Latest Safety News

Page 15 of 252
Spacetalk Limited (ASX:SPA) has posted a sharply deeper FY26 loss and negative net assets, while its auditor flagged a material uncertainty over the company’s ability to continue as a going concern. The company says a $10 million post-year-end placement, note conversions and new telco agreements give its software-led strategy room to execute.
Victor Sage
Victor Sage
28 Sept 2026
Zimplats delivered a sharp FY2026 earnings rebound, with revenue up 57% and profit after tax rising to US$276.7 million. The result was driven mainly by stronger PGM prices, while lower sales volumes, higher unit costs, no dividend and rising sulphur dioxide emissions temper the celebration.
Maxwell Dee
Maxwell Dee
28 Sept 2026
Kelsian Group delivered record FY26 earnings and lifted its fully franked dividend, while preparing to become a more focused bus, coach and ferry operator. The next test is execution: completing the conditional tourism sale, mobilising new contracts and delivering against FY27 EBITDA guidance.
Victor Sage
Victor Sage
25 Sept 2026
Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.
Victor Sage
Victor Sage
24 Sept 2026
Nexsen has paused its StrepSure clinical programme after an interim review identified performance improvements needed before a US FDA submission, pushing the target timetable back by roughly one quarter. Its shares were then suspended pending an announcement about a potentially material contract for an additional device.
Ada Torres
Ada Torres
24 Sept 2026
Saferoads Holdings Limited (ASX:SRH) returned to profit in FY2026 after product sales more than doubled, helped by $5.18 million of purchases from On-Site Rental Group. The result marks progress after the Road Safety Rentals disposal, but the next test is whether growth can continue without a repeat commitment from its largest customer.
Victor Sage
Victor Sage
23 Sept 2026
Prescient Therapeutics has raised approximately $6 million through its Share Purchase Plan and a shortfall placement, giving PTX-100 additional funding beyond a key clinical review in December. The next test is whether early results support a move into Phase 2b development.
Ada Torres
Ada Torres
23 Sept 2026
Paradigm Biopharmaceuticals has secured a voluntary suspension of its ASX securities while it prepares to release interim analysis results from its PARA_OA_012 Phase 3 trial. The announcement gives no indication whether the clinical readout is favourable or unfavourable, with trading potentially resuming on 28 September subject to ASX approval.
Victor Sage
Victor Sage
23 Sept 2026
Patrys has dosed the first participants in the Phase 1a trial of RLS-2202, moving its intravenous quetiapine formulation into human clinical evaluation. The next test comes in October, when an independent safety committee will decide whether the program can advance to Cohort 2.
Victor Sage
Victor Sage
23 Sept 2026
Actinogen Medical has completed the final patient visit in its 247-participant XanaMIA Alzheimer’s disease trial, keeping topline results on track for November 2026. The milestone closes patient participation in the pivotal study, but provides no indication yet of whether Xanamem improved outcomes.
Ada Torres
Ada Torres
23 Sept 2026
Dimerix has drawn A$17 million from a non-dilutive facility, giving the biotech funding it says is sufficient to complete the ACTION3 Phase 3 trial of DMX-200 and continue developing DMX-652. A further A$17 million remains available, although repayment depends partly on future licensing income, milestones or capital-market access.
Ada Torres
Ada Torres
23 Sept 2026
AdAlta has secured a formal US FDA pre-IND meeting for EW-001, moving its mesothelioma CAR-T therapy into a critical regulatory review. The November meeting will test the company’s Australian manufacturing, remaining studies and proposed Phase 1 trial before the more expensive stages of development begin.
Ada Torres
Ada Torres
23 Sept 2026

Browse the archive

Full archive